# Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

> **NCT02866682** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 176 (actual)

## Conditions studied

- Renal Transplant Rejection

## Interventions

- **DRUG:** Prograf
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02866682
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-01
- **Primary completion:** 2021-06-11
- **Final completion:** 2021-06-11
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02866682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02866682, "Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02866682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*